Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Makers Laboratories Ltd (MAKERSL)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506919 NSE: MAKERSL Pharmaceuticals & Drugs | Small Cap | Makers Laboratories Share Price
₹184.50 1.90 (1.04%)
As on 23-Sep'26 11:43
Makers Laboratories Ltd (MAKERSL)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506919 NSE: MAKERSL Pharmaceuticals & Drugs | Small Cap | Makers Laboratories Share Price
₹184.50 1.90 (1.04%)
As on 23-Sep'26 11:43
Key Metrics
Valuation Multiples
Market Cap
₹108 Cr.
Current Price
₹184.5
52-Week Low / High
₹109 / 237
TTM EPS
₹5.8
TTM Sales
₹148 Cr.
Book Value per Share
₹131.4
P/E Ratio
31.50
Industry PE
54.8
Price to Book (P/B)
1.39
Lower than its 5-year historical median
Price to Sales (P/S)
0.73
Lower than its 5-year historical median
EV/EBITDA
5.39
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
10.96%
Outperforms industry median
Return on Capital Employed (ROCE)
15.83%
Outperforms industry median
Return on Assets (ROA)
5.00%
Operating Profit Margin
10.6%
Net Profit Margin
5.59%
Gross Profit Margin
11.2%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
17.26%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
76.64%
Net Profit Growth (1 Year)
-
-27.96%
Asset Quality
Promoter Holding
61.27%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹72 Cr.
Equity
₹5.9 Cr.
Face Value
₹10
All Time Low / High
₹3.88 / 330.82
Check Before You Invest
Quality
Somewhat GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Weak
Is Makers Laboratories Ltd a good quality company?
Makers Laboratories Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Makers Laboratories Ltd performance compare with that of its Peers?
Revenue growth of Makers Laboratories Ltd vs industry peers?
Makers Laboratories Ltd revenue CAGR is 15.42%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Makers Laboratories Ltd?
Promoters hold 61.27% of the Makers Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Makers Laboratories Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 10.6% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Makers Laboratories Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 18.1% | 12.5% | 7.6% | 1.8% | -0.8% | 3.1% | -8% | -8% | 9.7% | -2.6% | - |
| Value Creation Index ⓘ | 0.3 | -0.1 | -0.5 | -0.9 | -1.1 | -0.8 | -1.6 | -1.6 | -0.3 | -1.2 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 58.1 | 56 | 46.6 | 51.4 | 44.4 | 52.4 | 42.6 | 49.1 | 42.9 | 50.4 | 47 |
| Sales YoY Gr. | - | -3.8% | -16.7% | 10.2% | -13.6% | 18% | -18.8% | 15.4% | -12.5% | 17.3% | - |
| Adj EPS ⓘ | 6.1 | 6.3 | 5.1 | 0.2 | -3.4 | 0.4 | -10.8 | -11.8 | -4.1 | -2.9 | -4.3 |
| YoY Gr. | - | 2.4% | -19.4% | -95.3% | -1508.3% | NA | -2609.3% | NA | NA | NA | - |
| BVPS (₹) ⓘ | 66.5 | 71.9 | 81.4 | 87.1 | 96.8 | 102.3 | 98.8 | 87.2 | 95 | 92.3 | 90.4 |
| Adj Net Profit ⓘ | 3.1 | 3.2 | 2.6 | 0.1 | -1.7 | 0.2 | -6.4 | -7 | -2.4 | -1.7 | -3 |
| Cash Flow from Ops. ⓘ | 5.5 | 0.2 | 5.4 | 4.2 | 0.7 | 6.8 | -1.4 | -3.1 | -1.6 | -2 | - |
| Debt/CF from Ops. ⓘ | 0.3 | 6.1 | 1.2 | 2.5 | 20.6 | 2.5 | -6.5 | -4.4 | -0.2 | -1.3 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -1.6% | 2.5% | 5.8% | 17.3% | ||||
| Adj EPS ⓘ | -192.1% | NA | NA | NA | ||||
| BVPSⓘ | 3.7% | -1% | -2.3% | -2.9% | ||||
| Share Price | 10.7% | -1.4% | 20% | 33.5% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 10.4 | 9.1 | 6.6 | 0.3 | -3.7 | 0.4 | -11.7 | -12.7 | -4.5 | -3.1 | -4.7 |
| Op. Profit Mgn % ⓘ | 8.9 | 8.3 | 5.2 | 6 | 7.5 | 5.9 | -9.7 | -7.6 | -5.1 | 1.5 | -0.5 |
| Net Profit Mgn % ⓘ | 5.4 | 5.8 | 5.6 | 0.2 | -3.9 | 0.4 | -15 | -14.2 | -5.7 | -3.4 | -5.4 |
| Debt to Equity ⓘ | 0 | 0 | 0.2 | 0.2 | 0.3 | 0.3 | 0.2 | 0.3 | 0 | 0.1 | - |
| Working Cap Days ⓘ | 134 | 158 | 193 | 165 | 200 | 168 | 196 | 169 | 183 | 157 | 76 |
| Cash Conv. Cycle ⓘ | 75 | 98 | 117 | 82 | 94 | 88 | 107 | 83 | 68 | 60 | 9 |
Valuation of Makers Laboratories - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|
| Sales | 69 | 127 | 101 | 104 | 121 | 141 |
| Operating Expenses ⓘ + | 61 | 108 | 98 | 103 | 112 | 126 |
| Operating Profit ⓘ | 8 | 19 | 3 | 1 | 8 | 15 |
| Operating Profit Margin (%) | 11.8% | 14.8% | 3.3% | 1.1% | 6.9% | 10.5% |
| Other Income ⓘ + | 1 | 3 | 2 | 2 | 12 | 2 |
| Interest ⓘ | 2 | 2 | 2 | 2 | 1 | 1 |
| Depreciation ⓘ | 5 | 4 | 4 | 5 | 5 | 5 |
| Profit Before Tax ⓘ | 3 | 16 | -1 | -4 | 13 | 11 |
| Tax ⓘ | 1 | 4 | 1 | 1 | 3 | 3 |
| Profit After Tax | 1 | 12 | -2 | -5 | 11 | 8 |
| PAT Margin (%) | 2.0% | 9.2% | -2.2% | -4.6% | 9.0% | 5.6% |
| Adjusted EPS (₹) | -0.6 | 10.1 | -8.1 | -10.6 | 12.7 | 4.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 54 | 60 | 69 | 63 | 71 | 73 | |||||
| Debt + | 12 | 14 | 9 | 16 | 2 | 4 | |||||
| Minority Interest | 32 | 39 | 40 | 41 | 45 | 50 | |||||
| Trade Payables | 15 | 5 | 10 | 17 | 12 | 20 | |||||
| Others Liabilities ⓘ | 23 | 26 | 24 | 24 | 19 | 21 | |||||
| Total Liabilities ⓘ | 136 | 144 | 152 | 161 | 148 | 167 | |||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 71 | 68 | 85 | 87 | 74 | 71 | |||||
| CWIP ⓘ | 0 | 9 | 0 | 0 | 1 | 4 | |||||
| Investments ⓘ | 2 | 0 | 0 | 3 | 0 | 12 | |||||
| Inventories | 27 | 24 | 31 | 34 | 34 | 45 | |||||
| Trade Receivables | 17 | 14 | 20 | 20 | 28 | 20 | |||||
| Cash Equivalents | 6 | 9 | 4 | 2 | 1 | 1 | |||||
| Others Assets ⓘ | 12 | 20 | 12 | 16 | 10 | 15 | |||||
| Total Assets ⓘ | 136 | 144 | 152 | 161 | 148 | 167 | |||||
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 0 | 18 | -9 | 1 | -4 | 14 |
| Cash Flow From Investing Activity ⓘ + | 0 | -22 | 1 | -7 | 20 | -15 |
| Cash Flow From Financing Activity ⓘ + | 0 | 0 | 6 | 6 | -16 | 0 |
| Net Cash Flow ⓘ | 0 | -3 | -2 | -0 | -0 | -0 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 2.49 | 20.61 | -3.4 | -7.28 | 16.33 | 10.96 | ||||
| ROCE (%) | 6.53 | 24 | 1.72 | -2.36 | 19.01 | 15.83 | ||||
| Asset Turnover Ratio | 0.5 | 0.91 | 0.68 | 0.67 | 0.78 | 0.89 | ||||
| PAT to CFO Conversion(x) | 0 | 1.5 | N/A | N/A | -0.36 | 1.75 | ||||
| Working Capital Days | ||||||||||
| Receivable Days | 88.30 | 43.30 | 60.20 | 69.50 | 72.40 | 62.20 | ||||
| Inventory Days | 146.10 | 73.60 | 99.40 | 113.90 | 102.50 | 102.50 | ||||
| Payable Days | 192.30 | 72.70 | 72.90 | 94.30 | 99.30 | 90.10 | ||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Makers Laboratories Ltd FAQs
The current trading price of Makers Laboratories on 23-Sep-2026 11:43 is ₹184.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Sep-2026 the market cap of Makers Laboratories stood at ₹107.7 Cr
The latest P/E ratio of Makers Laboratories as of 22-Sep-2026 is 0.00.
The latest P/B ratio of Makers Laboratories as of 22-Sep-2026 is 2.02.
The 52-week high of Makers Laboratories is ₹236.6 and the 52-week low is ₹109.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Makers Laboratories is ₹46.81 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Makers Laboratories Ltd is a average quality company.
The key valuation ratios of Makers Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Makers Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Makers Laboratories Ltd
Makers Laboratories was incorporated in 1985. The company is promoted and managed by Ipca Laboratories group. The company is engaged in manufacturing pharmaceutical formulations and drug intermediaries. The company’s plants are located in Palghar and Dombivli in Thane (Maharashtra). The company has a prominent presence in the therapeutic segment of antibiotics.
Makers Drugs & Food Products was amalgamated with the company with effect from April 1, 1993. In the year 2006 Makers Laboratories informed that Purnima Jain has been appointed as an additional director of the company and designated as the whole-time director with effect from October 30, 2006.
The registered office of the company is located at 54 D,Kandivli Industrial Estates, Kandivli west Mumbai, Maharashtra- 400067 .
Products
- Tablets & Capsules
- Liquids (Oral)
- Injectables
- Drugs (Intermediates)
- Creams & Ointments
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
